Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Lancet Child Adolesc Health. 2018 Sep 1;2(10):744–754. doi: 10.1016/S2352-4642(18)30236-0

Table 3.

Characteristics of electrophysiological findings among pediatric cancer populations during, and off treatment

Article Patient Population Timing of Testing Neurotoxic Agent CV – Motor Nerves Assessed: % abnormal CV – Sensory Nerves Assessed: % abnormal CMAP Nerves Assessed: % abnormal SNAP Nerves Assessed: % abnormal
On-Treatment
Kavcic et al 201729 Mixed Tumor Types (67% ALL) n=39
Age: 10 ± 6·4		 After minimum of 4 doses Vincristine Median, ulnar: 7%
Tibial, peroneal: 11%		 Median, ulnar: 48%
Sural: 7%		 Median, ulnar: 33%
Tibial, peroneal: 48%		 Median, ulnar: 67%
Sural: 11%
Yildiz & Temucin 201628 Mixed Tumor Types with suspected neuropathy (80% ALL) n=25
Age: mean 7·2 ± 4·8		 49·3 ± 28·6 days Vincristine Median, ulnar, tibial, peroneal and sural:
WNL		 Median, ulnar, peroneal and sural:
WNL		 Median, ulnar, tibial, peroneal and sural:
Group data significantly decreased		 Median, ulnar, tibial, peroneal and sural:
WNL
Toopchizadeh et al 200930 Mixed Tumor Types (60% ALL) n=42
Age: mean 6·2		 5 weeks after initiation of chemotherapy Vincristine Median, Tibial:
WNL		 Median, Sural:
WNL		 Tibial, median, and ulnar:
ALL 96% Other cancers 52·9%		 Median, ulnar, Sural:
WNL
Off Treatment
Kandula et al 201831 Mixed tumor types (52% Leukemia) n= 121
Age: median 16 (range 7–47)		 Median 8.5 years (1·5 – 29) Vincristine or Platinum - Sural:
WNL		 Tibial and Peroneal:
WNL		 Median: WNL Sural:
Vinc 18%
Plat 39%
Tay et al 201722 ALL n=101
Age: mean 11·8 ± 3·8		 >2 years Vincristine Common peroneal, tibial, median, ulnar:
61·4%* 		Sural, medial, ulnar, radial:
55%* 		Common peroneal, tibial, median, ulnar:
61·4%*		 Sural, medial, ulnar, radial:
55%*
Jain et al 201432 ALL n=77
Age: mean 11·2 ± 3·9		 within 3 years Vincristine Peroneal, Tibial, Median, and Ulnar:
WNL		 Sural, Ulnar, Median:
WNL		 Median, Ulnar: 7·8%
Peroneal, Tibial: 50·7%		 Sural, Ulnar, Median:
WNL
Ramchandren et al 20095 ALL n=37
Age: mean 14·4 ± 2·8		 >2 years Vincristine - - Median: 8%
Peroneal: 21%		 Median: 5%
Sural: WNL
*

Unclear if abnormality reported was CV or amplitude, ALL Acute Lymphoblastic Leukemia, CMAP Compound Muscle Action Potential, CV Conduction Velocity, SNAP Sensory nerve action potential, WNL Result was Within Normal Limits